Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
复制标题
甲氨蝶呤会在免疫介导的炎症性疾病中对BNT162B2 mRNA Covid-19疫苗的免疫原性。
DOI：
10.1136/annrheumdis-2021-220597
复制
发表时间：
2021-10
影响因子：
27.4
通讯作者：
Scher JU
中科院分区：
文献类型：
--
作者：
Haberman RH;Herati R;Simon D;Samanovic M;Blank RB;Tuen M;Koralov SB;Atreya R;Tascilar K;Allen JR;Castillo R;Cornelius AR;Rackoff P;Solomon G;Adhikari S;Azar N;Rosenthal P;Izmirly P;Samuels J;Golden B;Reddy SM;Neurath MF;Abramson SB;Schett G;Mulligan MJ;Scher JU
目的探讨免疫介导型炎症性疾病(IMID)免疫调节治疗患者对新冠肺炎疫苗的体液免疫和细胞免疫应答。纽约大学朗格尼健康中心确诊的51例接受BNT162b2mRNA疫苗接种的IMID患者在基线和第二次免疫后进行了评估。健康受试者(n=26)。对S蛋白的免疫球蛋白抗体反应进行体液反应分析。高参数流式细胞术进一步分析SARS-CoV-2的细胞免疫应答。来自德国Erlangen的第二个独立、有效的对照组(n=182)和IMID患者(n=31)也进行了体液免疫反应分析。虽然健康受试者(n=208)和接受生物治疗的IMID患者(主要使用肿瘤坏死因子阻滞剂，n=37)表现出较强的抗体应答(超过90%)，但接受甲氨蝶呤背景治疗的IMID患者(n=45)仅有62.2%的患者有足够的应答。同样，服用甲氨蝶呤的IMID患者在接种疫苗后CD8+T细胞活化没有增加。在两个独立的IMID患者队列中，被广泛用于治疗多种IMID的免疫调节剂甲氨蝶呤对新冠肺炎基因疫苗的体液和细胞免疫反应产生了不利影响。尽管与疫苗效力相关的免疫原性的准确界限尚未确定，但我们的发现表明，在服用甲氨蝶呤的IMID患者中，可能需要探索不同的策略，以增加对SARS-CoV-2的免疫效力的机会，正如已经证明的那样，增强对其他病毒疫苗的免疫原性。
To investigate the humoral and cellular immune response to messenger RNA (mRNA) COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMIDs) on immunomodulatory treatment. Established patients at New York University Langone Health with IMID (n=51) receiving the BNT162b2 mRNA vaccination were assessed at baseline and after second immunisation. Healthy subjects served as controls (n=26). IgG antibody responses to the spike protein were analysed for humoral response. Cellular immune response to SARS-CoV-2 was further analysed using high-parameter spectral flow cytometry. A second independent, validation cohort of controls (n=182) and patients with IMID (n=31) from Erlangen, Germany, were also analysed for humoral immune response. Although healthy subjects (n=208) and patients with IMID on biologic treatments (mostly on tumour necrosis factor blockers, n=37) demonstrate robust antibody responses (over 90%), those patients with IMID on background methotrexate (n=45) achieve an adequate response in only 62.2% of cases. Similarly, patients with IMID on methotrexate do not demonstrate an increase in CD8+ T-cell activation after vaccination. In two independent cohorts of patients with IMID, methotrexate, a widely used immunomodulator for the treatment of several IMIDs, adversely affected humoral and cellular immune response to COVID-19 mRNA vaccines. Although precise cut-offs for immunogenicity that correlate with vaccine efficacy are yet to be established, our findings suggest that different strategies may need to be explored in patients with IMID taking methotrexate to increase the chances of immunisation efficacy against SARS-CoV-2 as has been demonstrated for augmenting immunogenicity to other viral vaccines.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
27.4
作者：
Park, Jin Kyun;Lee, Min Ah;Lee, Eun Bong
通讯作者：
Lee, Eun Bong
影响因子：
27.4
作者：
Park, Jin Kyun;Lee, Yun Jong;Lee, Eun Bong
通讯作者：
Lee, Eun Bong
影响因子：
16.6
作者：
Simon, David;Tascilar, Koray;Schett, Georg
通讯作者：
Schett, Georg
影响因子：
82.9
作者：
Amanat F;Stadlbauer D;Strohmeier S;Nguyen THO;Chromikova V;McMahon M;Jiang K;Arunkumar GA;Jurczyszak D;Polanco J;Bermudez-Gonzalez M;Kleiner G;Aydillo T;Miorin L;Fierer DS;Lugo LA;Kojic EM;Stoever J;Liu STH;Cunningham-Rundles C;Felgner PL;Moran T;García-Sastre A;Caplivski D;Cheng AC;Kedzierska K;Vapalahti O;Hepojoki JM;Simon V;Krammer F
通讯作者：
Krammer F